ZENITHDRUG — Zenith Drugs Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Zenith Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	R2023 March 31st	R2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	—	1,145	1,316	1,333	1,712
Cost of Revenue
Gross Profit	—	364	461	458	487
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	—	1,068	1,175	1,230	1,653
Operating Profit	—	77.4	142	104	59
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	44	66.6	133	92.6	53.9
Provision for Income Taxes
Net Income After Taxes	—	48.8	95.4	71.6	39.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	—	48.8	95.4	71.6	39.4
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	—	48.8	95.4	71.6	39.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	—	2.85	6.21	4.29	2.39
Dividends per Share